Procter & Gamble seeks approval of Teva OTC takeover

Published: 12-Nov-2012
Finance Pharmaceutical

EC competition department will decide this month whether to clear acquisition


The European Commission competition department will decide this month (November) whether to clear Procter & Gamble’s acquisition of a second tranche of the over-the-counter (OTC) pharmaceutical business from Israel’s Teva Pharmaceuticals.

Procter & Gamble bought OTC services from Teva last year and now wants to buy more of the business, which Teva acquired from Cephalon in 2011.

  • Companies:
  • Procter and Gamble
See more

You may also like

Distribution

Teva Pharmaceuticals identifies risk to European medicine supply security in new research

Read more
The generic drug manufacturer warns that the European supply chain of critical generic medicines is not diversified, relying on a select few companies to distribute oncology, cardiology, antibiotic and mental health therapeutics

Trending Articles

  1. European life sciences investors kick off 2026 with targeted bets on immunity, oncology and metabolic health From thymus regeneration and ECM-targeted oncology to fast-scaling metabolic health technology, three European companies secure fresh capital as investors double down on differentiated science with clear commercial momentum
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    From pilots to production: what 2026 could mean for pharma This editorial examines predictions from the HSBC Innovation Banking Life Sciences and Healthcare team on how innovation, investment and consolidation are expected to shape the market in 2026
  3. Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
  4. Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation The long-term funding will enable the BioInnovation Institute to expand into new scientific fields and European markets, strengthening translation of academic research into commercial life sciences innovation
  5. EIB and Angelini Ventures launch €150m fund to boost European biotech, medtech and digital health startups The EIB and Angelini Ventures will co-invest €150 million to scale innovative European healthtech companies. The deal marks the EIB’s first partnership with a corporate venture capital fund in the healthcare sector

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Distribution

Teva Pharmaceuticals identifies risk to European medicine supply security in new research

The generic drug manufacturer warns that the European supply chain of critical generic medicines is not diversified, relying on a select few companies to distribute oncology, cardiology, antibiotic and mental health therapeutics
Distribution

Teva Pharmaceuticals, Klinge Pharma and Formycon join forces to commercialise Eylea biosimilar

FYB203, which will be marketed under the name AHZANTIVE®3 if approved by the EMA, will be commercialised by Teva Pharmaceuticals in the majority of Europe and Israel
Research & Development

Teva & Medincell release Phase III SOLARIS trial results for olanzapine in schizophrenic adults

The results indicate that Medincell's TEV-'749 subcutaneous extended release device for the administration of olanzapine in schizophrenic adults met primary and secondary endpoints
Manufacturing

Europe’s generic medicines are disappearing, study finds

Over a ten year period, the number of generic medicines withdrawn from the market increased by 12%
Manufacturing

Teva Pharmaceuticals gives a look into each step of sterile medicine production

Teva Pharmaceuticals has released a video showing production steps at a site that manufactures 480 million doses a year
Research & Development

Teva completes facilities purchase in Pennsylvania

Investment will see the Israeli drug-maker set up a Research & Development campus in the US
Manufacturing

Teva signs deal for ‘Digital Twins’ to improve production

The three-year deal with Insilico will aim to transform data generated every day into measurable improvements to production processes
Subscribe now